On December 12, Ntimbwe Munongo Mpamba will celebrate his fortieth birthday with chocolate cake in Northgate, Johannesburg. He was born with HIV but only became aware of his HIV status many years later. Biénne Huisman spoke to him about living with HIV, his early years when his mother fed him medicine disguised as sweets, and now, living openly as an HIV awareness champion.
In 2019, the Department of Health started providing the antiretroviral drug dolutegravir as part of HIV treatment in the public sector. Three years later, close to 3.2 million people in South Africa are taking dolutegravir every day. Even so, the rollout of dolutegravir hasn’t all been smooth sailing. Elri Voigt investigates how the massive undertaking of switching millions of people to a new drug has gone.
One of the biggest breakthroughs in HIV treatment in the 1990s came when three different antiretrovirals were used together, suppressing viral replication in multiple ways and preventing the development of drug resistance. Now, trials are showing that certain combinations of just two antiretrovirals might be as good as three, potentially bringing an end to a quarter of a century of triple therapy dominance. Elri Voigt reports.
Many clinics in Limpopo are operating without the required number of staff needed to deliver quality healthcare services, according to a report from Ritshidze, a community healthcare monitoring project. Activists say these staff shortages contribute to long waiting times for patients and overworked staff – which can ultimately undermine the province’s HIV programme.
Too many clinics are in crisis and it is driving the continuing HIV epidemic. People are dying because of it, argue members of the Ritshidze Project as they launch a report into the state of public sector facilities in Gauteng.
